Media coverage about Stryker (NYSE:SYK) has been trending somewhat positive on Saturday, Accern Sentiment reports. Accern identifies negative and positive press coverage by analyzing more than 20 million news and blog sources in real time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Stryker earned a news impact score of 0.13 on Accern’s scale. Accern also gave news articles about the medical technology company an impact score of 46.9744898240468 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the next several days.
Here are some of the media stories that may have effected Accern’s rankings:
- Stryker Corporation to Post Q3 2018 Earnings of $1.66 Per Share, SunTrust Banks Forecasts (SYK) (americanbankingnews.com)
- Stryker Corp (SYK) Files 10-K for the Fiscal Year Ended on December 31, 2017 (finance.yahoo.com)
- Stryker Corporation (SYK) Plans $0.47 Quarterly Dividend (americanbankingnews.com)
- Q2 2018 Earnings Estimate for Stryker Corporation (SYK) Issued By SunTrust Banks (americanbankingnews.com)
- Free Post Earnings Research Report: Stryker’s Quarterly Revenue Jumped 10%; Adjusted Earnings Advanced 10.5% (finance.yahoo.com)
A number of equities analysts have weighed in on SYK shares. Robert W. Baird raised Stryker from a “neutral” rating to an “outperform” rating and boosted their target price for the stock from $161.00 to $173.00 in a research report on Thursday, November 16th. Needham & Company LLC reissued a “hold” rating on shares of Stryker in a research report on Friday, November 3rd. JPMorgan Chase & Co. raised Stryker from a “neutral” rating to an “overweight” rating in a research report on Tuesday, January 2nd. ValuEngine raised Stryker from a “hold” rating to a “buy” rating in a research report on Tuesday, November 14th. Finally, Piper Jaffray Companies reissued a “buy” rating and issued a $156.00 target price on shares of Stryker in a research report on Friday, October 27th. Two equities research analysts have rated the stock with a sell rating, nine have assigned a hold rating and fourteen have given a buy rating to the company’s stock. The company presently has an average rating of “Hold” and an average price target of $162.50.
Stryker (NYSE:SYK) last announced its quarterly earnings data on Tuesday, January 30th. The medical technology company reported $1.96 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $1.95 by $0.01. The company had revenue of $3.47 billion during the quarter, compared to the consensus estimate of $3.42 billion. Stryker had a return on equity of 24.55% and a net margin of 8.20%. The firm’s revenue was up 9.9% on a year-over-year basis. During the same period in the previous year, the company posted $1.78 EPS. research analysts predict that Stryker will post 7.12 earnings per share for the current year.
The business also recently disclosed a quarterly dividend, which will be paid on Monday, April 30th. Investors of record on Thursday, March 29th will be paid a dividend of $0.47 per share. The ex-dividend date of this dividend is Wednesday, March 28th. This represents a $1.88 dividend on an annualized basis and a dividend yield of 1.24%. Stryker’s dividend payout ratio (DPR) is presently 70.15%.
In other Stryker news, VP William E. Berry, Jr. sold 1,306 shares of the company’s stock in a transaction that occurred on Thursday, February 1st. The stock was sold at an average price of $164.42, for a total value of $214,732.52. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Howard E. Cox, Jr. sold 7,400 shares of the company’s stock in a transaction that occurred on Friday, February 2nd. The stock was sold at an average price of $164.09, for a total value of $1,214,266.00. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 16,840 shares of company stock valued at $2,749,989. 7.40% of the stock is currently owned by corporate insiders.
TRADEMARK VIOLATION WARNING: “Stryker (SYK) Given Daily News Sentiment Score of 0.13” was reported by Sports Perspectives and is owned by of Sports Perspectives. If you are reading this article on another domain, it was stolen and reposted in violation of United States and international trademark & copyright laws. The correct version of this article can be read at https://sportsperspectives.com/2018/02/10/stryker-syk-given-daily-news-sentiment-score-of-0-13.html.
Stryker Company Profile
Stryker Corporation is a medical technology company. The Company offers a range of medical technologies, including orthopedic, medical and surgical, and neurotechnology and spine products. The Company’s segments include Orthopaedics; MedSurg; Neurotechnology and Spine, and Corporate and Other. The Orthopaedics segment includes reconstructive (hip and knee) and trauma implant systems and other related products.
Receive News & Ratings for Stryker Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stryker and related companies with MarketBeat.com's FREE daily email newsletter.